BlackRock Amends PMV Pharma Stake, Remains Passive Investor
Ticker: PMVP · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1699382
| Field | Detail |
|---|---|
| Company | Pmv Pharmaceuticals, Inc. (PMVP) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of PMV Pharma, but it's a passive stake.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in PMV Pharmaceuticals, Inc. as of December 31, 2023. This filing, Amendment No. 3, indicates BlackRock's continued significant, but passive, stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and its holdings can signal confidence or a lack thereof in a company's long-term prospects, even if its stake has slightly changed.
Why It Matters
BlackRock's continued passive ownership in PMV Pharmaceuticals, Inc. suggests institutional confidence, which can influence other investors' perceptions and the stock's stability.
Risk Assessment
Risk Level: low — This filing is routine for large institutional investors and doesn't indicate any immediate or significant risk to PMV Pharmaceuticals, Inc. or its shareholders.
Analyst Insight
An investor should note that BlackRock's continued passive stake in PMV Pharmaceuticals, Inc. suggests a long-term, hands-off investment strategy, which might be viewed as a stable endorsement, but doesn't signal any imminent strategic changes or activist involvement.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person filing the SC 13G/A
- PMV Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 3 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document and what does it signify?
This document is an SC 13G/A, which is an amendment to a Schedule 13G. It signifies that BlackRock, Inc., a large institutional investor, is updating its previously reported beneficial ownership of common stock in PMV Pharmaceuticals, Inc. and confirms its passive investment intent under Rule 13d-1(b).
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742, a security broker, dealer, and flotation company based in New York, NY.
Who is the subject company in this filing?
The subject company is PMV Pharmaceuticals, Inc., identified by CIK 0001699382, a pharmaceutical preparations company based in Princeton, NJ.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, indicating the ownership position as of the end of the last calendar year.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b), which is typically used by institutional investors (like BlackRock) who hold more than 5% of a company's stock but do not intend to influence or control the company.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding PMV Pharmaceuticals, Inc. (PMVP).